Post A Reply
Allstocks.com's Bulletin Board
.11 and Up!
CTIX -- Cellceutix Corporation
» Post A Reply
Post A Reply
HTML is enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by BooDog: [QB] The Phase 1 study with Kevetrin, CTIX-0000, is in progress at DanaFarber/Harvard Cancer Center in subjects with various solid carcinomas; the majority of which are gynecological cancers. 10 cohorts of subjects have been completed; the 11th cohort is ongoing. Only 1 DLT has been observed to date, but the MTD has not yet been reached. The current dose is 750 mg/m2, 75-fold greater than the starting dose. Kevetrin was shown to activate wild type p53 and degrade mutant p53. Since Kevetrin activates both transcriptional-dependent and transcriptional-independent pathways to promote apoptosis through wild type p53 activation and degrades oncogenic mutant p53, Kevetrin can function as a major inducer of apoptosis in many types of tumors independent of p53 mutation status. In this Phase 1 study, the biomarker, p21 expression levels in peripheral blood, were increased in 68% of subjects and 48% had an increase in p21 expression at a level of ≥10%. These results suggest that Kevetrin activates p53 by inducing p21 gene expression ACO 2015 presentation by Dr. Shapiro http://cellceutix.com/wp-content/uploads/2015/05/ASCO-2015-Poster-.-FINAL-1.pdf [URL=http://cellceutix.com/asco-2015-a-phase-1-dose-escalation-safety-pharmacokinetic-pharmacodynamic-study-of-thioureidobutyronitrile-a-novel-p53-targeted-therapy-in-patients-with-advanced-solid-tumors/#sthash.rJyxGqez.Ykj69KYo.dpbs]http://cellceutix.com/asco-2015-a-phase-1-dose-escalation-safety-pharmacokinetic -pharmacodynamic-study-of-thioureidobutyronitrile-a-novel-p53-targeted-therapy-i n-patients-with-advanced-solid-tumors/#sthash.rJyxGqez.Ykj69KYo.dpbs[/URL] [/QB][/QUOTE]
Instant UBB Code™
What is UBB Code™?
Disable Graemlins in this post.
*** Click here to review this topic. ***
Allstocks.com Message Board Home
© 1997 - 2018 Allstocks.com. All rights reserved.